Piper Sandler, Nektar
Piper Sandler Issues Overweight Rating for Nektar Therapeutics (NKTR) Stock
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 and touched a low of $1.
GlobalData on MSN18h
Nektar Therapeutics to sell Alabama facility to AmpersandThe transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of ...
Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...
After Close of U.S.-Based Financial Markets Nektar Therapeutics will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback